Palvella Therapeutics (PVLA) Long-Term Investments (2017 - 2022)
Palvella Therapeutics (PVLA) reported Long-Term Investments of $20.3 million for Q2 2022, up 1193.31% quarter-over-quarter from $1.6 million in Q2 2020.
Palvella Therapeutics (PVLA) Long-Term Investments (2017 - 2022) Analysis & Trends
Palvella Therapeutics (PVLA) has 5 years of Long-Term Investments data on file, last reported at $20.3 million in Q2 2022.
- Long-Term Investments for Q2 2022 came in at $20.3 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2022 was $20.3 million (changed N/A YoY), and the FY2017 annual result was $9.9 million, changed N/A from the prior year.
- Long-Term Investments climbed to $20.3 million in Q2 2022 per PVLA's latest filing, from $1.6 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $20.3 million in Q2 2022 and troughed at $700000.0 in Q2 2018.
- A 4-year average of $6.7 million and a median of $2.6 million in 2018 frame the typical range for Long-Term Investments.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 20.29 Mn |
| Jun 30, 2020 | 1.57 Mn |
| Sep 30, 2019 | 8.44 Mn |
| Jun 30, 2018 | 700,000.00 |
| Mar 31, 2018 | 2.58 Mn |
| Dec 31, 2017 | 9.92 Mn |